Mark David Novara net worth and biography

Mark Novara Biography and Net Worth

Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care

Mark Novara has served as our Executive Vice President and Chief Commercial Officer since November 2023. Mr. Novara is an executive with nearly 25 years of general management, strategy and marketing experience in the medical device, life science and pharmaceutical industries. Before joining our Company, he served as Senior Advisor in the Medical Technology/Life Science practice at McKinsey & Company since February 2023. Before that time, Mr. Novara held executive positions at Becton Dickinson for more than 11 years, most recently as a Worldwide Vice President/General Manager in the Medication Delivery Solutions business unit from June 2020 to December 2022. He also served as Senior Vice President, Global Strategic Marketing for two of BD’s segments, Medical from May 2018 to June 2020, and, Life Sciences from December 2015 to May 2018. Mr. Novara was also a Worldwide Vice President/General Manager in the Diabetes Care business unit from November 2013 to December 2015, and, Director of Strategic Marketing and Business Development in the Pharmaceutical Systems business unit from July 2011 to November 2013. He also held leadership positions with Hoffman-La Roche and Sanofi-Aventis. Mr. Novara received a BS in Biology from Villanova University and a Masters in Healthcare Management from Columbia University.

What is Mark David Novara's net worth?: The estimated net worth of Mark David Novara is at least $878.14 thousand as of March 17th, 2026. Mr. Novara owns 37,656 shares of Tandem Diabetes Care stock worth more than $878,138 as of March 26th. This net worth evaluation does not reflect any other investments that Mr. Novara may own. Learn More about Mark David Novara's net worth.
How do I contact Mark David Novara?: The corporate mailing address for Mr. Novara and other Tandem Diabetes Care executives is 11075 ROSELLE STREET, San Diego CA, 92121. Tandem Diabetes Care can also be reached via phone at (858) 366-6900 and via email at [email protected]. Learn More on Mark David Novara's contact information.
Has Mark David Novara been buying or selling shares of Tandem Diabetes Care?: During the past quarter, Mark David Novara has sold $4,355.97 in Tandem Diabetes Care stock. Most recently, Mark David Novara sold 187 shares of the business's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $23.05, for a transaction totalling $4,310.35. Following the completion of the sale, the executive vice president now directly owns 37,656 shares of the company's stock, valued at $867,970.80. Learn More on Mark David Novara's trading history.
Who are Tandem Diabetes Care's active insiders?: Tandem Diabetes Care's insider roster includes Dick Allen (Director), David Berger (EVP), Kim Blickenstaff (Director), Elizabeth Gasser (EVP), Brian Hansen (EVP), Shannon Hansen (Executive Vice President, Chief Legal, Privacy and Compliance Officer and Secretary), Jean-Claude Kyrillos (Executive Vice President and Chief Operating Officer), James Leal (SVP), Kathleen McGroddy-Goetz (Director), Susan Morrison (EVP), Mark Novara (Executive Vice President and Chief Commercial Officer), Rebecca Robertson (Director), John Sheridan (CEO), Christopher Twomey (Director), and Leigh Vosseller (CFO). Learn More on Tandem Diabetes Care's active insiders.
Are insiders buying or selling shares of Tandem Diabetes Care?: In the last twelve months, Tandem Diabetes Care insiders bought shares 2 times. They purchased a total of 23,720 shares worth more than $251,710.80. In the last twelve months, insiders at the medical device company sold shares 2 times. They sold a total of 189 shares worth more than $4,355.97. The most recent insider tranaction occured on March, 17th when EVP Mark David Novara sold 187 shares worth more than $4,310.35. Insiders at Tandem Diabetes Care own 1.9% of the company. Learn More about insider trades at Tandem Diabetes Care.
Information on this page was last updated on 3/17/2026.

Mark David Novara Insider Trading History at Tandem Diabetes Care

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/17/2026	Sell	187	$23.05	$4,310.35	37,656
3/5/2026	Sell	2	$22.81	$45.62	35,969
11/15/2024	Buy	532	$23.24	$12,363.68	532

Mark David Novara Buying and Selling Activity at Tandem Diabetes Care

Tandem Diabetes Care Company Overview

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Today's Range

Now: $23.32

$22.98

$24.30

50 Day Range

MA: $21.66

$18.52

$28.26

2 Week Range

Now: $23.32

$9.98

$29.65

Volume

1,805,503 shs

Average Volume

2,014,260 shs

Market Capitalization

$1.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63